Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 7/20 | 0.43 |
| ▸ | BRPF1 | P55201 | 4/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | BRD1 | O95696 | 1/20 | 0.42 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3661663 | 0.90 | GSK3B (0.42) | GSK3BTSHRCYP2D6 | |
| SCHEMBL3663404 | 0.89 | GSK3B (0.41) | GSK3BCYP2D6 | |
| SCHEMBL3662859 | 0.89 | GSK3B (0.45) | GSK3BBRPF1BRD4BRD1BRPF3 | |
| SCHEMBL3663942 | 0.89 | KCNMA1 (0.44) | ALDH1A1MAPTGSK3BPOLB | |
| SCHEMBL2065326 | 0.88 | KMT2A (0.46) | ALDH1A1GLAMAPTKMT2AGSK3B | |
| SCHEMBL3658243 | 0.87 | GSK3B (0.40) | GSK3BCYP2D6 | |
| SCHEMBL2065962 | 0.87 | KMT2A (0.46) | ALDH1A1GLAMAPTKMT2AGSK3B | |
| SCHEMBL3655065 | 0.85 | GSK3B (0.42) | ALDH1A1KMT2AGSK3BTSHRPOLB | |
| SCHEMBL3724856 | 0.83 | KDM4D (0.41) | ALDH1A1GLAMAPTKMT2AGSK3B | |
| SCHEMBL3663726 | 0.82 | GSK3B (0.44) | GSK3BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238141-A1 | SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | claimed |
| WO-2009095789-A1 | SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA | SANOFI-AVENTIS (FR) | 2009-08-06 | — | — | WO | claimed |
| EP-2238141-A1 | SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009095789-A1 | SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA | SANOFI-AVENTIS (FR) | 2009-08-06 | — | — | WO | disclosed |